Please login to the form below

Not currently logged in
Email:
Password:

Antiretroviral therapy

This page shows the latest Antiretroviral therapy news and features for those working in and with pharma, biotech and healthcare.

NHS England will make PrEP for HIV available in April

NHS England will make PrEP for HIV available in April

The PrEP Impact Trial is using Mylan's generic version of Gilead Sciences’ antiretroviral therapy Truvada (emtricitabine/tenofovir disoproxil) but is due to come to an end in October.

Latest news

  • Gilead drug reduces HIV viral reservoir, says researcher Gilead drug reduces HIV viral reservoir, says researcher

    suppression prior to starting antiretroviral therapy (ART). ... Stem cell transplants are high-risk procedures, so the treatment wouldn’t be suitable as a routine therapy for HIV-positive people.

  • FDA rejects ViiV’s long-acting monthly HIV injection FDA rejects ViiV’s long-acting monthly HIV injection

    ATLAS involved pateints who had been previously treated with long-acting antiretroviral therapy (ART), and showed that the combination injection matched standard therapy on viral suppression rates. ... Three patients treated with ViiV’s injectable (1%)

  • Dovato approval key for Glaxo in HIV treatment Dovato approval key for Glaxo in HIV treatment

    ViiV already have another two-in-one STR, Juluca (dolutegravir/rilpivirine), but this is only approved for HIV patients who have achieved viral suppression with another antiretroviral therapy. ... The HIV therapy market is also likely to be affected by

  • GSK, J&J say monthly injection keeps HIV controlled GSK, J&J say monthly injection keeps HIV controlled

    The long-acting antiretroviral therapy (ART) could mean that more patients adhere to the treatment regimen needed to suppress HIV, and avoid the risk of skipped doses that can help viral ... If approved, this two-drug regimen would give people living

  • GSK’s says depot HIV injection works over three years GSK’s says depot HIV injection works over three years

    Moreover, patients in a control arm receiving standard oral antiretroviral therapy (ART) who elected to swap over to the injectable regimen after 96 weeks did so without loss of viral suppression, ... combinations GSK is hoping will simplify HIV therapy

More from news
Approximately 1 fully matching, plus 42 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story
How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
AI healthcare
Three ways AI will change healthcare in the next decade
Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...

Infographics